AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05761236 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Sessions are consisted of scoliosis-specific pilates-based exercises.The exercises were kept constant in total content, but the bilateral or unilateral application directions, the number of repetitions for the right and left sides, and the extremities used were modified for each patient according to the localization of the major curve and the type of the curve. The taught postural corrections were requested to be maintained during all exercises. Exercises for flexibility were performed asymmetrically or symmetrically according to the chosen exercise, extremities were chosen according to the curve type, with 5 repetitions and 30 seconds for each repetition. Exercises aimed at strengthening were performed for a total of 12 repetitions, during a 5-second contraction, by arranging the number of repetitions for the right and left in line with the target muscles, again considering the curve type, and the patients were asked to rest between the exercises.
Study NCT05012007 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reminder Phone
Description: Standard reminder via phone (audiocare)
Study NCT05012007 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reminder Text
Description: reminder via text (VEText)
Study NCT04918953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: The patients were treated with three protocols: (1) oral methylprednisolone, 40 mg for 3 days, 20 mg for 3 days, and 8 mg for 6 days; (2) oral methylprednisolone, 20 mg for 3 days, 10 mg for 3 days, and 4 mg for 6 days. At the same time, all patients received olfactory training for 12 weeks as proposed by Hummel et al
Study NCT04918953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide atomization suspension
Description: (3) budesonide atomization suspension (AstraZeneca Trading Co., Ltd, AU.) inhaled through the nose atomized with an air compression atomizer for 4 weeks, 2 mg for the first 2 weeks and reduced to 1 mg for the last 2 weeks. At the same time, all patients received olfactory training for 12 weeks as proposed by Hummel et al
Study NCT05273021 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: TAPS
Description: all participants are investigated by the Dutch TAPS tool (Tobacco, Alcohol, Prescription medication and other Substances-tool). A screener and short assessment of possible substance use problems
Study NCT05254405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexanolone Injection [Zulresso]
Description: Continuous infusion of brexanolone over 60 hours titrated to a maximal dose of 90 mcg/kg/hr.
Study NCT05227599 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Online survey questionnaire
Description: Participants will complete a brief online survey every morning and evening within 1 hour of waking and 1 hour of going to sleep. The surveys will be a combination of measures used to assess affect, stress, and symptoms
Study NCT05181202 — intervention group
Intervention type: OTHER
Intervention: Blood sampling
Description: Collect blood before drug injection. we do not intervene the clinical administration or drug choice or other clinical treatment.
Study NCT04840563 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kalifon A
Description: Commercially available kalifilcon A lenses
Study NCT04840563 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dailies Total1
Description: Dailies Total1
Study NCT04840563 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Precision1
Description: Precision1
Study NCT06223776 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sleep restriction
Description: Participants will experience a night of acute sleep restriction. During this night, they will sleep 3 hours less than usual.
Study NCT06391164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XC243 25 mg
Description: Patients will receive the Investigated Product (IP) once in the morning at least 30 minutes before eating for 7-10 days
Study NCT06391164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XC243 50 mg
Description: Patients will receive the IP once in the morning at least 30 minutes before eating for 7-10 days
Study NCT06391164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XC243 75 mg
Description: Patients will receive the IP once in the morning at least 30 minutes before eating for 7-10 days
Study NCT06391164 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive the IP once in the morning at least 30 minutes before eating for 7-10 days
Study NCT05378594 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Nasal allergen challenge
Description: graded nasal allergen challenge to increasing concentrations of allergen with monitoring of nasal symptoms and peak nasal inspiratory flow
Study NCT05432661 — intervention group
Intervention type: DEVICE
Intervention: HİGH-FLOW NASAL OXYGEN USE (HFNO)
Description: It is aimed to show that the use of HFNO can improve oxygenation compared to the use of nasal cannula in ERCP procedures performed under sedation in the prone position.
Study NCT06491810 — intervention group
Intervention type: OTHER
Intervention: Arm crank exercise
Description: The arm ergometer exercise will be the only intervention implemented during the study.
Study NCT04798469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Undecanoate 250 MG/ML
Description: Intramuscular administration at a dose of 750 mg at baseline, weeks 4, and week 14.
Study NCT04798469 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular administration of placebo at baseline, weeks 4, and week 14.
Study NCT05411679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EP0057
Description: EP0057 is an investigational nanoparticle-drug conjugate with a Camptothecin payload, that is administered intravenously
Study NCT05411679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib tablets
Description: Olaparib is a PARP inhibitor (poly \[adenosine diphosphate-ribose\] polymerase inhibitor) Other names: Lynparza
Study NCT05415085 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Culprit-first PCI
Description: PCI to the culprit artery prior to the demonstration of the whole coronary tree.
Study NCT05789979 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The resident-handling device
Description: Care staff will perform resident-handling tasks using the new resident-handling devices. For low dependency during trial, the device helps care staff to assist residents in making a transition from a sit to a standing posture, vice versa. This device is used for functional activities and transferring and lifting participants. For high dependency during trial, when care staff are performing resident-handling tasks, the device moves with little force in any direction.
Study NCT06233864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disitamab Vedotin
Description: Disitamab Vedotin
Study NCT06233864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine
Study NCT06380088 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric Task
Description: The exercise required participants to keep their arm flexed at a 90° angle while holding a dumbbell loaded to 80% of their 1RM (One Rep Max) in a supine position on the dominant side of the body for as long as possible.
Study NCT06443840 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AutonHome® device
Description: The experimental group will have to carry out the programme of self-rehabilitation and tele-rehabilitation with the AutonHome® device in addition to conventional rehabilitation.
Study NCT05618964 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deep Neck Flexors & Extensors exercises
Description: Deep neck flexor exercises (2 set of 10 repetitions) that includes:~Contraction of deep neck flexor muscle in supine Craniocervical flexion in supine~Deep Neck Extensor exercises (2 set of 10 repetitions) that includes:~Contraction of deep neck extensors in quadruped position Segmented extension movement with the head bent down onto their chest in a horizontal direction,
Study NCT05003154 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digitalized management
Description: In addition to conventional management, Patients also receive digitalized management, which provides personalized guidance in diet, excercise, prenatal visit, blood glucose monitoring,etc., from artificail intelliegence (AI) supevised by obstetricians, through a smartphone application and some werable devices (like sports bracelet).~The pivotal AI are based on clinical experience from obstetricians, therapeutic principle from official Guidelines and abundant data in previous work, and it will works under strict supervision.
Study NCT04780152 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: Participants receive 10 consecutive sessions followed by 1 session per week 10 weeks of tDCS (30 minutes and 2 mA). Anodal stimulation will be applied on F3 according to the intentional 10/20 system, and the cathode will be applied on the contra lateral position (F4).
Study NCT04780152 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-simulation of transcranial direct current stimulation
Description: Participants receive 10 consecutive sessions followed by 1 session per week 10 weeks of placebo (30 minutes of placebo-simulation tDCS). Placebo will be administered using the same stimulation parameters and the active treatment position of the electrodes, but current wil be aborted 30 seconds after the ascending slope has begun.
Study NCT04780152 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluoxetine Tablets
Description: Every patient will receive 10 mg of fluoxetine daily the first 2 two weeks, followed by 20 mg daily.
Study NCT04780152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine Tablets
Description: Every patient will receive 10 mg of fluoxetine daily the first 2 two weeks, followed by 20 mg daily.
Study NCT06508268 — intervention group
Intervention type: BEHAVIORAL
Intervention: GAITRite walkway system OR 4-meter walking speed test
Description: Gait will be assessed by the GAITRite walkway system OR the 4-meter walking speed test
Study NCT06508268 — intervention group
Intervention type: BEHAVIORAL
Intervention: Jamar hand dynamometer
Description: Hand grip strength will be assessed by a Jamar hand dynamometer
Study NCT05296863 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Non-concentrated adipose-derived stem cell conditioned media and 5% Minoxidil
Description: Non-concentrated ADSC-CM is given during week 0, 2, 4, and 6 on the left side of the scalp.~Minoxidil is applied twice using a spray, in the morning and at night.
Study NCT05296863 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Concentrated adipose-derived stem cell conditioned media and 5% Minoxidil
Description: Intervention is given during week 0, 2, 4, and 6 on the left side of the scalp. Minoxidil is applied twice using a spray, in the morning and at night.
Study NCT05296863 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Placebo and 5% Minoxidil
Description: Intervention is given during week 0, 2, 4, and 6 on the right side of the scalp.~Minoxidil is applied twice using a spray, in the morning and at night.
Study NCT06019884 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Caries detection method: Intraoral camera
Description: A specialized intraoral camera (C50) with fluorescence signal and selective chromatic amplification will be used to record intraoral structures in the form of videos and/or photos. The camera has four modes (Daylight, Daylight+, Perio and Caries modes) which can differentiate the color of tissues to provide a reliable diagnosis. The camera will be used in a systemic sequence to video record and capture photos of intraoral conditions in both arches. The intraoral camera will be connected to a laptop screen, and the captured videos and/ or photos will be transferred to an electronic platform.
Study NCT06019884 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Caries detection method: Smartphone camera
Description: This is a low-cost electronic system consisting of a smartphone positioned in front of the oral cavity to scan the upper and lower jaws from the cheek then the tongue sides. The smartphone camera resolution should be sensitive enough to capture the intraoral structures (at least 1000 pixels). The focus will be adjusted, and the inbuilt flash will be used to obtain clear and sharp images. The photos will be transferred to the electronic platform.
Study NCT06019884 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Referral pathway: User fee removal
Description: The child's parent/ legal guardian will receive financial incentives. These a are designed to cover the costs of treatment and transportation and are tied to attending the preventive dental visit. The child will receive complete dental care.
Study NCT06019884 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Referral pathway: Conventional referral
Description: Children will be referred without providing financial incentives following the current standard of care in dental clinics in the public sector in Egypt. Care is planned by the receiving/ treating dentist, based on available resources, and hospital/ clinic policies. The screening/ sending dentist will inform the family about the oral health condition/s and planned treatment costs for which the child needs care and of available public and private facilities that offer the required care.
Study NCT04655001 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MORPH
Description: A 12-week movement and caloric restriction intervention meant to reduce pain and body weight.
Study NCT06508268 — intervention group
Intervention type: BEHAVIORAL
Intervention: Picture description task
Description: Characteristics Dutch/Frisian language Language and speech will be assessed by the Cookie Theft Picture-task (a picture description task from Berube et al., 2019)
Study NCT06508268 — intervention group
Intervention type: BEHAVIORAL
Intervention: Autobiographical semi-structured conversation
Description: Characteristics Dutch/Frisian language and speech will be assessed by an autobiographical semi-structured conversation
Study NCT06508268 — intervention group
Intervention type: BEHAVIORAL
Intervention: Verbal fluency
Description: The mental lexicon of Dutch/Frisian language will be assessed by a two verbal fluency tests, including letter fluency and categorical fluency
Study NCT06496789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serplulimab+SOX
Description: Serplulimab+Oxaliplatin+S1
Study NCT05635227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone phosphate
Description: See description of arms
Study NCT05635227 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic sodium chloride (0.9%)
Description: See description of arms
Study NCT05635227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine 10 MG
Description: Olanzapine tablet pre-hidden in capsule identical to the placebo tablet
Study NCT05635227 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: capsule identical to capsule containing olanzapine
Study NCT05635227 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Flow-targeted hemodynamic management
Description: See description of arms
Study NCT05635227 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pressure-targeted hemodynamic management
Description: See description of arms
Study NCT05635227 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low tidal-volume ventilation
Description: See description of arms
Study NCT05635227 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No ventilation
Description: See description of arms
Study NCT04663256 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive stimulation group
Description: Each week for 12 weeks, GE participants attend three 60-minute sessions of cognitive exercises.
Study NCT05549206 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine low dose
Description: 50μg/dose
Study NCT05720364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TP-05 (lotilaner oral), fasted group
Description: TP-05 (lotilaner oral), fasted group
Study NCT05720364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TP-05 (lotilaner oral), high-fat group
Description: TP-05 (lotilaner oral), high-fat group
Study NCT05720364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TP-05 (lotilaner oral), low-fat group
Description: TP-05 (lotilaner oral), low-fat group
Study NCT05424263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Acetate Oral Solution
Description: Subjects will be supplemented with calcium acetate (4,000 mg/day), as described in the arm/group descriptions, for 12 weeks.
Study NCT05424263 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Calcium Carbonate Oral Suspension
Description: Subjects will be supplemented with calcium carbonate (2,500 mg/day), as described in the arm/group descriptions, for 12 weeks.
Study NCT05238259 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: kinesiotaping
Description: Kinesio tape is the name of an adhesive tape created by Kenzo Kase in Japan in 1973. Kinesiotaping is latex-free with 100% cotton fibers that has no pharmaceutical effect, designed to mimic the elasticity properties of the muscle, skin, and fascia. These properties make it resistant and wearable for a long period, in general, 3 to 5 days at a time; it is even water resistant.
Study NCT05238259 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: wrist wheel
Description: Wrist wheel is a therapy aid that exercises muscles in the wrist, forearm and shoulder. It utilizes exercises known as pronation and supination moving from pronation to supination exercises is made easy because of the wheel. It allows the pateint to easily roll wrist back and forth focusing on the wrist and arm
Study NCT05549206 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine high dose
Description: 100μg/dose
Study NCT05642143 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Dual Energy X-ray Absorbtiometry scan
Description: Evaluation of body composition and bone mass density
Study NCT05549206 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline solution
Study NCT05642143 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: High-resolution peripheral quantitative computed tomography
Description: High-resolution peripheral quantitative computed tomography (HR-pQCT) assesses both volumetric bone mineral density (vBMD) and trabecular and cortical microarchitecture.
Study NCT05642143 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Microindentation
Description: Measures Bone Material Strength Index (BMSi) of cortical bone.
Study NCT05715008 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kefir
Description: Comparison of kefir and placebo consumption for 2 weeks on various parameters in healthy adult subjects
Study NCT05715008 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Comparison of kefir and placebo consumption for 2 weeks on various parameters in healthy adult subjects
Study NCT05066373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP1815 capsule A
Description: EDP1815 capsule A is an orally administered, pharmaceutical preparation of a single strain of Prevotella histicola. The capsule is radio-labeled with approximately 4 MBq 99mTc-DTPA
Study NCT05066373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP1815 capsule B
Description: EDP1815 capsule B is an orally administered, pharmaceutical preparation of a single strain of Prevotella histicola. The capsule is radio-labeled with approximately 4 MBq 99mTc-DTPA
Study NCT05066373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP1815 tablet
Description: EDP1815 tablet is an orally administered, pharmaceutical preparation of a single strain of Prevotella histicola. The tablet is radio-labeled with approximately 4 MBq 99mTc-DTPA
Study NCT06413342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Patients should receive their first dose of sintilimab within 42 days after completing the final radiotherapy session and continue treatment until disease progression, occurrence of intolerable toxicity, loss to follow-up, death, or as determined by the investigator, whichever comes first. The maximum duration of sintilimab treatment is 12 months (from the initiation of therapy). No other anti-tumor therapies are permitted during the treatment period.
Study NCT05783115 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tibial Transportation Combined With Autologous mesenchymal stem cells Local Infusion
Description: transverse bone transport with bone marrow cell transplantation
Study NCT05783115 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tibial Transportation
Description: transverse bone transport
Study NCT05652998 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: C. albicans antigen
Description: a test dose (0.1 ml) of the C. albicans antigen will be injected intradermally into the skin of the forearm. A reaction will be considered positive in presence of ≥5 mm erythema and induration after 48-72 hr. Only reactors will be included. patients will receive intralesional injection of candida antigen at a dose 0.1 ml of 1/1000 solution into the largest wart at 3 weekly intervals for a total of 3 doses.